PMA device
Trulign Toric Posterior Chamber Intraocular Lens
Bausch & Lomb, Inc. · Lens, Intraocular, Toric Optics (MJP, Class III) · First FDA decision May 20, 2013, newest Jun 2, 2015Cataract
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
1
Naming "Trulign"
MAUDE reports
0
Brand "Trulign", since 2015
PubMed studies
5
Mentioning "Trulign"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Trulign Toric Posterior Chamber Intraocular Lens
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 3 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Trulign", any status and sponsor, newest update first.
Bausch & Lomb IncorporatedNot on our public-company list
NCT02394379 · 600 participants (planned) · Start Mar 19, 2015 · Primary completion Aug 5, 2019
Device: Trulign™ Toric IOL · For: Cataract
Sites: Rochester, New York
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Trulign", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MJP
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Trulign"[tiab]. The summary above synthesizes these.
- Benefits and barriers of accommodating intraocular lenses.
Pepose JS, Burke J, Qazi MA · Curr Opin Ophthalmol · 2017Review
- Visual and Refractive Outcomes of a Toric Presbyopia-Correcting Intraocular Lens.
Epitropoulos AT · J Ophthalmol · 2016
- Toric intraocular lens orientation and residual refractive astigmatism: an analysis.
Potvin R, Kramer BA, Hardten DR, et al. · Clin Ophthalmol · 2016
- Safety and effectiveness of a new toric presbyopia-correcting posterior chamber silicone intraocular lens.
Pepose JS, Hayashida J, Hovanesian J, et al. · J Cataract Refract Surg · 2015Multicenter Study, Randomized Controlled Trial
- Intracorneal ring segments followed by toric pseudoaccomodating IOL for treatment of patients with corneal ectasia and cataract.
Konda S, Ambati BK · Am J Ophthalmol Case Rep · 2020
Other devices of this type
Also filed under product code MJP.
- TECNIS Toric 1-Piece Intraocular Lenses (IOL)Johnson & Johnson Surgical Vision, Inc. · PMA 2020
- Crystalens and Trulign Toric Intraocular Lenses (Iols)Bausch & Lomb, Inc. · PMA 2016
- enVista One-Piece Hydrophobic Acrylic Toric Intraocular Lens (Model MX60T)Bausch & Lomb, Inc. · PMA 2018
- Crystalens Accommodating Intraocular Lens & Trulign Toric Intraocular LensBausch & Lomb, Inc. · PMA 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.